Last reviewed · How we verify
CSTC1
At a glance
| Generic name | CSTC1 |
|---|---|
| Sponsor | Charsire Biotechnology Corp. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia (PHASE2)
- BAC in Patient With Alzheimer's Disease or Vascular Dementia (PHASE2)
- CSTC1 for Diabetic Foot Ulcers Phase II Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSTC1 CI brief — competitive landscape report
- CSTC1 updates RSS · CI watch RSS
- Charsire Biotechnology Corp. portfolio CI